ST. LOUIS, Feb. 11, 2013 /PRNewswire/ -- With governmental markets at all levels coping with severe budget constraints, and hospital equipment markets also in recession, Allied Healthcare Products (NASDAQ: AHPI) reported a loss for the second quarter of fiscal year 2013.
Net income for the quarter ending December 3, 2012 represented a loss of about $469,000, or a negative 6 cents per basic and diluted share, versus about $23,000, or zero cents per basic and diluted share for the prior year. Sales for the quarter declined from about $10.7 million to $9.9 million, or about 7.5 percent, from the previous year.
For the first two quarters of fiscal 2013, net income was a negative $880,000, or a negative 11 cents per basic and diluted share, compared to negative net income of $123,000 or negative 2 cents per basic and diluted share, for the prior year. Sales for the first two quarters slipped from about $22.1 million to $19.2 million, or about 13.1 percent, from the previous year.
A bright spot in Allied sales came from international markets. For the first half of the year, international sales increased almost 19 percent over the previous year.
Increases in global markets, however, could not offset continued decline in Allied's domestic hospital construction business. Sales in the domestic construction market fell about 36 percent compared to the prior year.
Sales of Allied's new carbon dioxide absorbent Litholyme®, used in anesthesia procedures, were hindered by product introduction delays, Allied reported. However, those problems have been resolved, and U.S. hospitals are adopting the advanced product.
"Overall, our domestic carbon dioxide absorbent sales are up nearly 17 percent in the first half," said Earl Refsland , Allied Healthcare Products president and chief executive offi
|SOURCE Allied Healthcare Products|
Copyright©2012 PR Newswire.
All rights reserved